A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms FORWARD
- Sponsors Biogen
- 15 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 31 Jul 2015 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020 as per ClinicalTrials.gov record.
- 31 Jul 2015 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020 as per ClinicalTrials.gov record.